 |
Texas Statutes (Last Updated: January 4, 2014) |
 |
GOVERNMENT CODE |
|
Title 4. EXECUTIVE BRANCH |
|
Subtitle I. HEALTH AND HUMAN SERVICES |
|
Chapter 531. HEALTH AND HUMAN SERVICES COMMISSION |
|
Subchapter B. POWERS AND DUTIES |
Sec. 531.0691. MEDICAID DRUG UTILIZATION REVIEW PROGRAM: DRUG USE REVIEWS AND ANNUAL REPORT
-
(a) In this section:
(1) "Medicaid Drug Utilization Review Program" means the program operated by the vendor drug program to improve the quality of pharmaceutical care under the Medicaid program.
(2) "Prospective drug use review" means the review of a patient's drug therapy and prescription drug order or medication order before dispensing or distributing a drug to the patient.
(3) "Retrospective drug use review" means the review of prescription drug claims data to identify patterns of prescribing.
(b) The commission shall provide for an increase in the number and types of retrospective drug use reviews performed each year under the Medicaid Drug Utilization Review Program, in comparison to the number and types of reviews performed in the state fiscal year ending August 31, 2009.
(c) In determining the number and types of drug use reviews to be performed, the commission shall:
(1) allow for the repeat of retrospective drug use reviews that address ongoing drug therapy problems and that, in previous years, improved client outcomes and reduced Medicaid spending;
(2) consider implementing disease-specific retrospective drug use reviews that address ongoing drug therapy problems in this state and that reduced Medicaid prescription drug use expenditures in other states; and
(3) regularly examine Medicaid prescription drug claims data to identify occurrences of potential drug therapy problems that may be addressed by repeating successful retrospective drug use reviews performed in this state and other states.
(d) In addition to any other information required by federal law, the commission shall include the following information in the annual report regarding the Medicaid Drug Utilization Review Program:
(1) a detailed description of the program's activities; and
(2) estimates of cost savings anticipated to result from the program's performance of prospective and retrospective drug use reviews.
(e) The cost-saving estimates for prospective drug use reviews under Subsection (d) must include savings attributed to drug use reviews performed through the vendor drug program's electronic claims processing system and clinical edits screened through the prior authorization system implemented under Section 531.073.
(f) The commission shall post the annual report regarding the Medicaid Drug Utilization Review Program on the commission's website.